Vortioxetine for the Treatment of Depression

Annals of Pharmacotherapy

Volumn 48, Issue 6, 2014, Pages 758-765

  Pearce, Erica F ^a   Murphy, Julie A ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

depression; Lu AA21004; major depressive disorder; vortioxetine

Indexed keywords

AMFEBUTAMONE; CARBAMAZEPINE; DULOXETINE; FLUOXETINE; OMEPRAZOLE; PAROXETINE; PHENYTOIN; PLACEBO; QUINIDINE; RIFAMPICIN; VENLAFAXINE; VORTIOXETINE; WARFARIN; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; SULFIDE;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; EVALUATION STUDY; FATIGUE; GASTROENTERITIS; HAMILTON SCALE; HEADACHE; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; REMISSION; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA; DEPRESSIVE DISORDER, MAJOR;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; PIPERAZINES; SEROTONIN AGENTS; SULFIDES;

EID: 84899726814     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014528305     Document Type: Article

References (36)

1. Ferrari AJ,Charlson FJ,Norman RE,et al.Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease Study 2010.PLoS Med. 2013;10:e1001547.
2. Current depression among adults: United States, 2006 and 2008.MMWR Morb Mortal Wkly Rep. 2010;59:1229-1235.
3. Papkostas GI.Limitations of contemporary antidepressants: tolerability.J Clin Psychiatry. 2007;68:11-17.
4. Warden D,Rush AJ,Trivedi MH,Fava M,Wisniewski SR.The STAR*D Project results; a comprehensive review of the findings.Curr Psychiatry Rep. 2007;9:449-459.
5. Zimmerman M,Chelminski I,Posternak M.A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression.Int Clin Psychopharmacol. 2004;19:1-7.
6. Israel JA.Remission in depression: definition and initial treatment approaches.J Psychopharmacol. 2006;20:5-10.
7. Nierenberg AA,Wright EC.Evolution of remission as the new standard in the treatment of depression.J Clin Psychiatry. 1999;60:7-11.
8. Zimmerman M,McGlinchey JB,Posternak MA,Friedman M,Attiullah N,Boerescu D.How should remission from depression be defined? The depressed patient's perspective.Am J Psychiatry. 2006;163:148-150.
9. Hawley CJ,Gale TM,Sivakumaran T.Defining remission by cut off score on the MADRS: selecting the optimal value.J Affect Disord. 2002;72:177-184.
10. Thase ME,Entsuah AR,Rudolph RL.Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.Br J Psychiatry. 2001;178:234-241.
11. Rush AJ,Trivedi MH,Wisniewski SR,et al.Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.N Engl J Med. 2006;354:1231-1242.
12. Mallinckrodt CH,Goldstein DJ,Detke MJ,Lu Y,Watkin JG,Tran PV.Duloxetine: a new treatment for the emotional and physical symptoms of depression.Prim Care Companion J Clin Psychiatry. 2003;5:19-28.
13. GelenbergAJFreemanMPMarkowitzJC. Practice guideline for the treatment of patients with major depressive disorder. November2010. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485. Accessed November 6, 2013.
14. Deerfield, IL: Takeda Pharmaceuticals American, Inc; 2013
15. Areberg J,Luntang-Jensen M,Søgaard B,Nilausen DØ.Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects.Basic Clin Pharmacol Toxicol. 2012;110:401-404.
16. Adell A.Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.IDrugs. 2010;13:900-910.
17. Bang-Andersen B,Ruhland T,Jørgensen M,et al.Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.J Med Chem. 2011;54:3206-3221.
18. Areberg J,Søgaard B,Højer AM.The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers.Basic Clin Pharmacol Toxicol. 2012;111:198-205.
19. Hvenegaard MG,Bang-Andersen B,Pedersen H,Jørgensen M,Puschl A,Dalgaard L.Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004.Drug Metab Dispos. 2012;40:1357-1365.
20. Alvarez E,Perez V,Dragheim M,Loft H,Artigas F.A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.Int J Neuropsychopharmacol. 2012;15:589-600.
21. Baldwin DS,Loft H,Dragheim M.A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).Eur Neuropsychopharmacol. 2012;22:482-491.
22. Henigsberg N,Mahableshwarkar AR,Jacobsen P,Chen Y,Thase ME.A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.J Clin Psychiatry. 2012;73:953-959.
23. Katona C,Hansen T,Olsen CK.A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.Int Clin Psychopharmacol. 2012;27:215-223.
24. Jain R,Mahableshwarkar AR,Jacobsen PL,Chen Y,Thase ME.A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.Int J Neuropsychopharmacol. 2013;16:313-321.
25. Mahableshwarkar AR,Jacobsen PL,Chen Y.A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.Curr Med Res Opin. 2013;29:217-226.
26. Mahableshwarkar AR,Jacobsen PL,Serenko M,Chen Y,Trivedi MH.A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses of vortioxetine (Lu AA21004) in acute treatment of adults with major depressive disorder [poster NR9-02]. Poster presented at: American Psychiatric Association Annual Meeting; San Francisco, CA;.
27. Jacobsen PL,Mahableshwarkar AR,Serenko M,Chan S,Trivedi MH.A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder [poster NR9-06]. Poster presented at: American Psychiatric Association Annual Meeting; San Francisco, CA;.
28. Mahableshwarkar AR,Jacobsen PL,Serenko M,Chen Y,Trivedi MH.A duloxetine-referenced, fixed-dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult MDD patients [poster NR9-01]. Poster presented at: American Psychiatric Association Annual Meeting; San Francisco, CA;.
29. Boulenger JP,Loft H,Olsen CK.Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.Int Clin Psychopharmacol:.
30. Boulenger JP,Loft H,Florea I.A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.J Psychopharmacol. 2012;26:1408-1416.
31. Baldwin DS,Hansen T,Florea I.Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.Curr Med Res Opin. 2012;28:1717-1724.
32. Alam MY,Jacobsen PL,Chen Y,Serenko M,Mahableshwarkar AR.Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.Int Clin Psychopharmacol. 2014;29:36-44.
33. Filippov G,Christens PF.Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability study in major depressive disorder. Poster presented at: 26th European College of Neuropsychopharmacology Congress; Barcelona, Spain;.
34. Chen G,Lee R,Højer AM,Buchbjerg JK,Serenko M,Zhao Z.Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.Clin Drug Investig. 2013;33:727-736.
35. Theunissen EL,Street D,Højer AM,Vermeeren A,van Oers A,Ramaekers JG.A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition.Clin Pharmacol Ther. 2013;93:493-501.
36. Citrome L.Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.Int J Clin Pract. 2014;68:60-82.